What Analysts Are Saying About Jazz Pharmaceuticals Stock
Ratings for Jazz Pharmaceuticals (NASDAQ:JAZZ) were provided by 11 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 2 | 8 | 1 | 0 | 0 |
| Last 30D | 1 | 0 | 0 | 0 | 0 |
| 1M Ago | 0 | 0 | 0 | 0 | 0 |
| 2M Ago | 1 | 5 | 1 | 0 | 0 |
| 3M Ago | 0 | 3 | 0 | 0 | 0 |
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $206.0, along with a high estimate of $247.00 and a low estimate of $155.00. This upward trend is evident, with the current average reflecting a 16.68% increase from the previous average price target of $176.55.
Investigating Analyst Ratings: An Elaborate Study
In examining recent analyst actions, we gain insights into how financial experts perceive Jazz Pharmaceuticals. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Ami Fadia | Needham | Raises | Buy | $235.00 | $210.00 |
| David Amsellem | Piper Sandler | Raises | Overweight | $219.00 | $147.00 |
| Ashwani Verma | UBS | Raises | Neutral | $188.00 | $163.00 |
| Mohit Bansal | Wells Fargo | Raises | Overweight | $235.00 | $170.00 |
| Joel Beatty | Baird | Raises | Outperform | $209.00 | $160.00 |
| Jason Gerberry | B of A Securities | Raises | Buy | $247.00 | $230.00 |
| Leonid Timashev | RBC Capital | Raises | Outperform | $194.00 | $155.00 |
| Jeffrey Hung | Morgan Stanley | Raises | Overweight | $205.00 | $185.00 |
| Leonid Timashev | RBC Capital | Raises | Outperform | $155.00 | $151.00 |
| Jessica Fye | JP Morgan | Lowers | Overweight | $199.00 | $204.00 |
| Jeffrey Hung | Morgan Stanley | Raises | Overweight | $180.00 | $167.00 |
Key Insights:
- Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Jazz Pharmaceuticals. This insight gives a snapshot of analysts' perspectives on the current state of the company.
- Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Jazz Pharmaceuticals compared to the broader market.
- Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Jazz Pharmaceuticals's stock. This comparison reveals trends in analysts' expectations over time.
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Jazz Pharmaceuticals's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
Stay up to date on Jazz Pharmaceuticals analyst ratings.
Unveiling the Story Behind Jazz Pharmaceuticals
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
Jazz Pharmaceuticals: A Financial Overview
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Jazz Pharmaceuticals's revenue growth over a period of 3M has been noteworthy. As of 30 September, 2025, the company achieved a revenue growth rate of approximately 6.74%. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Jazz Pharmaceuticals's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 22.33%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Jazz Pharmaceuticals's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 6.56%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Jazz Pharmaceuticals's ROA excels beyond industry benchmarks, reaching 2.25%. This signifies efficient management of assets and strong financial health.
Debt Management: With a high debt-to-equity ratio of 1.37, Jazz Pharmaceuticals faces challenges in effectively managing its debt levels, indicating potential financial strain.
Understanding the Relevance of Analyst Ratings
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
This article was generated by Benzinga's automated content engine and reviewed by an editor.